Main Content
latest…
Photon Control downgraded to “Hold” at Paradigm Capital
Ahead of the company's fourth quarter results, Paradigm Capital analyst Kevin Krishnaratne has … Keep reading
More recent headlines
Cannabis
iAnthus Capital is trading at a 70 per cent discount to its peers, Beacon says
Following the closing of a (US) $35-million financing, Beacon Securities analyst Russell Stanley remains bullish on iAnthus Capital (iAnthus Capital … Read More
See related
Stock Picks
Photon Control downgraded to “Hold” at Paradigm Capital
Ahead of the company's fourth quarter results, Paradigm Capital analyst Kevin Krishnaratne has lowered his price target and downgraded his rating on … Read more
See related
Life Sciences Stocks
Profound Medical is an undervalued life sciences stock for 2019, Echelon says
2018 didn't shape up exactly the way he had imagined, but Echelon Wealth Partners analyst Doug Loe … Keep reading
Mackie Research maintains “Hold” rating on Theratechnologies
Positive new data for Theratechnologies' (Theratechnologies Stock Quote, Chart TSX:TH) HIV treatment … Keep reading
Profound Medical is a breakout biotech stock for 2019, Paradigm Capital says
Ahead of the company's fourth quarter results, Paradigm Capital analyst Rahul Sarugaser is more than … Keep reading
Buy Kalytera Therapeutics for a 328 per cent return: Echelon Wealth
California-based drug developer Kalytera Therapeutics (Kalytera Therapeutics Stock Quote, Chart … Keep reading
Zymeworks has lots of upside, Paradigm Capital says
Paradigm Capital analyst Rahul Sarugaser is expecting 2019 to be a big clinical year for Zymeworks … Keep reading